Role of Sodium-Glucose Cotransporter 2 Inhibitors for Management of Diabetes Mellitus in Renal Transplant Recipients and Management Strategies for Posttransplant Hypertension
American Journal of Nephrology · 2023
DOI: 10.1159/000530296 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Nephrology, 2023. Verfasst von Amit Pal Singh und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, University of Maryland School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Kidney Transplantation, Diabetes Mellitus, Hypertension, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 57 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background: Diabetes mellitus and hypertension are the leading causes of cardiovascular disease in the renal transplant recipients. This review looks at the potential role of sodium-glucose cotransporter 2 inhibitors (SGLT2is) and reviews the management strategies for hypertension in this population. Summary: Large-scale clinical trials are needed to study the potential cardiorenal benefits and risks of complications in renal transplant recipients. Future clinical trials are also needed to define optimal blood pressure treatment goals and therapies and how they influence graft and patient survival. Key Messages: Multiple recent prospective randomized clinical trials have shown the benefits of using SGLT2is to improve the cardiorenal outcomes in patients with chronic kidney disease with or without diabetes mellitus. Renal transplant recipients were not included in these trials due to concerns about genitourinary complications; hence, the role of these agents in this population is unclear. A number of small studies have highlighted the safety of using these agents in renal transplant recipients. Posttransplant hypertension is a complex problem requiring individualized management. Recent guidelines recommend using a calcium channel blocker or angiotensin receptor blocker as the first-line antihypertensive agents in adult renal transplant recipients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Nephrology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Zitieren
APA
Singh, A. P., Kalil, R. S., & Weir, M. R. (2023). Role of Sodium-Glucose Cotransporter 2 Inhibitors for Management of Diabetes Mellitus in Renal Transplant Recipients and Management Strategies for Posttransplant Hypertension. American Journal of Nephrology. https://doi.org/10.1159/000530296
Vancouver
Singh AP, Kalil RS, Weir MR. Role of Sodium-Glucose Cotransporter 2 Inhibitors for Management of Diabetes Mellitus in Renal Transplant Recipients and Management Strategies for Posttransplant Hypertension. American Journal of Nephrology. 2023. doi:10.1159/000530296
BibTeX
@article{Singh2023,
author = {Singh, Amit Pal and Kalil, Roberto S and Weir, Matthew R},
title = {Role of Sodium-Glucose Cotransporter 2 Inhibitors for Management of Diabetes Mellitus in Renal Transplant Recipients and Management Strategies for Posttransplant Hypertension},
journal = {American Journal of Nephrology},
year = {2023},
doi = {10.1159/000530296}
}
EUVIMED